Who is this relevant for?
- Pharmaceutical buyers sourcing shortage medicines
- Hospitals managing supply risk
- Distributors monitoring sourcing opportunities
The MHRA has recalled all batches of quetiapine oral suspension manufactured by Eaststone Limited after a manufacturing error left the product with double the intended amount of quetiapine fumarate.
This is a recall in the UK unlicensed specials market, where products are supplied when licensed options are not suitable for an individual patient. In this case, the affected medicine was used in psychiatric care, including schizophrenia, bipolar disorder, and add-on treatment for depression.
For operators, the immediate issue is patient-level traceability. Eaststone told the MHRA it has full traceability of healthcare customers it supplied directly and has already started recall communications and action. That matters in specials supply, where products often move through narrower channels and recall execution depends on fast identification of each affected bottle and patient.
Only 166 bottles were manufactured between 26 October 2025 and 26 January 2026, but the operational burden is still high. Pharmacies and other healthcare professionals involved in dispensing the product have been told to identify and contact all affected patients at once to confirm whether any medicine remains in use. Patients who previously took affected batches may also be reviewed.
Pressure on replacement supply
The recall also creates an access problem. GPs and specialist clinicians are being asked to review patients quickly and consider ongoing treatment options, including switching to alternatives. That places pressure on pharmacy teams and supply partners to locate suitable replacement options without delay.
For buyers and distributors, the case is a reminder that unlicensed medicine supply depends on more than availability. It also depends on manufacturer controls, batch traceability, and the ability to support urgent substitution when a product is withdrawn.
Why this matters in specials
The source of the issue was a manufacturing error, not a distribution problem. Still, the downstream effect sits squarely with dispensers, prescribers, and supply teams. Once an unlicensed special is recalled, each handoff matters: who received stock, which patients were dispensed from affected batches, and what can replace the product for ongoing treatment.
The MHRA has directed stakeholders to the National Patient Safety Alert for batch details and further instructions. For organisations handling specials, this recall underlines a basic requirement in unlicensed medicine supply: tight records, clear recall workflows, and alternative sourcing routes that can be activated quickly when quality failures surface.